Only GLP-1R agonists, primarily used as antidiabetic/antiobesity drugs, are used as potential agents for NAFLD/NASH treatment, as demonstrated in several studies with mouse models. Here, GLP1R is linked to metabolic dysfunction-associated steatotic liver disease.